144 related articles for article (PubMed ID: 23247045)
1. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.
Bolaños-Meade J; Wu J; Logan BR; Levine JE; Ho VT; Alousi AM; Weisdorf DJ; Luznik L;
Biol Blood Marrow Transplant; 2013 Mar; 19(3):481-5. PubMed ID: 23247045
[TBL] [Abstract][Full Text] [Related]
2. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies for steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J; Vogelsang GB
Curr Opin Hematol; 2005 Jan; 12(1):40-4. PubMed ID: 15604890
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood lymphocyte subsets after allogeneic bone marrow transplantation: reconstitution and correlation with the occurrence of acute graft-versus-host disease.
Chan EY; Chiu EK; So MK; Lie AK; Chan TK
Asian Pac J Allergy Immunol; 1994 Dec; 12(2):117-23. PubMed ID: 7612104
[TBL] [Abstract][Full Text] [Related]
5. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
Bolaños-Meade J; Logan BR; Alousi AM; Antin JH; Barowski K; Carter SL; Goldstein SC; Hexner EO; Horowitz MM; Lee SJ; Levine JE; MacMillan ML; Martin PJ; Mendizabal AM; Nakamura R; Pasquini MC; Weisdorf DJ; Westervelt P; Ho VT
Blood; 2014 Nov; 124(22):3221-7; quiz 3335. PubMed ID: 25170121
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
8. Immune cell subset counts associated with graft-versus-host disease.
Podgorny PJ; Liu Y; Dharmani-Khan P; Pratt LM; Jamani K; Luider J; Auer-Grzesiak I; Mansoor A; Williamson TS; Ugarte-Torres A; Hoegh-Petersen M; Stewart DA; Daly A; Khan FM; Russell JA; Storek J
Biol Blood Marrow Transplant; 2014 Apr; 20(4):450-62. PubMed ID: 24406506
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
10. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
11. Analysis of immune reconstitution in children undergoing cord blood transplantation.
Moretta A; Maccario R; Fagioli F; Giraldi E; Busca A; Montagna D; Miniero R; Comoli P; Giorgiani G; Zecca M; Pagani S; Locatelli F
Exp Hematol; 2001 Mar; 29(3):371-9. PubMed ID: 11274766
[TBL] [Abstract][Full Text] [Related]
12. Transient T cell depletion causes regression of melanoma metastases.
Rasku MA; Clem AL; Telang S; Taft B; Gettings K; Gragg H; Cramer D; Lear SC; McMasters KM; Miller DM; Chesney J
J Transl Med; 2008 Mar; 6():12. PubMed ID: 18334033
[TBL] [Abstract][Full Text] [Related]
13. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
14. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
Lee S; Chong SY; Lee JW; Kim SC; Min YH; Hahn JS; Ko YW
Bone Marrow Transplant; 1997 Nov; 20(10):883-8. PubMed ID: 9404931
[TBL] [Abstract][Full Text] [Related]
15. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
Levine JE; Paczesny S; Mineishi S; Braun T; Choi SW; Hutchinson RJ; Jones D; Khaled Y; Kitko CL; Bickley D; Krijanovski O; Reddy P; Yanik G; Ferrara JL
Blood; 2008 Feb; 111(4):2470-5. PubMed ID: 18042798
[TBL] [Abstract][Full Text] [Related]
16. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
[TBL] [Abstract][Full Text] [Related]
18. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of lymphocyte subsets as a predictive factor for GVHD in allogeneic bone marrow transplantation.
Marin GH; Menna ME; Saba S; Klein G; Mendez MC; Bergna MI; Italiano C; Malacalza J; Perez M; Gil MA; Gardenal L; Orlando S; Mansilla E; Cánepa C; Piccinelli G
Transplant Proc; 1999 Nov; 31(7):2973-5. PubMed ID: 10578354
[No Abstract] [Full Text] [Related]
20. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.
Choi SW; Stiff P; Cooke K; Ferrara JL; Braun T; Kitko C; Reddy P; Yanik G; Mineishi S; Paczesny S; Hanauer D; Pawarode A; Peres E; Rodriguez T; Smith S; Levine JE
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1525-32. PubMed ID: 22469883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]